You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser
Site Exit Disclaimer
You are now leaving the website of Merck KGaA, Darmstadt, Germany’s biopharma business. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and makes no representation as to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third party website does not constitute an endorsement by our company of such website or the information or products presented on such website.
Share Disclaimer
By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.
Cookie Disclaimer
We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to permit. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Statement.
We invest a considerable amount of our global R&D efforts into oncology and immuno-oncology, with a focus on understanding the role of biomarkers in immuno-oncology.
Our aim is to discover and develop diverse treatment options and new approaches to cancer care to help more people with rare or hard-to-treat cancers live longer, healthier lives.
Together we’re working to build up our oncology pipeline with an immuno-oncology program covering 15 difficult-to-treat tumour types. As our work continues, we hope to uncover potential new medicines that can help meet patients’ many unmet medical needs.
